```html

Kernouve Disease (Keratoconjunctivitis Sicca)

What is Kernouve Disease?

Kernouve disease, medically known as keratoconjunctivitis sicca (KCS) or simply “dry eye,” is a chronic condition in which the eye does not produce enough tears, or the tears evaporate too quickly, leading to inadequate lubrication of the ocular surface. The name honors the French ophthalmologists Francois‑Pierre‑Alphonse Kern and Jacob Koufit, who first described the disorder in the early 20th century.

The tear film has three layers (lipid, aqueous, and mucin) that work together to keep the cornea clear, protect against infection, and provide comfort. When any of these layers are deficient, the eye becomes dry, gritty, and vulnerable to damage. Kernouve disease can affect one eye or both and ranges from mild irritation to severe visual impairment.

Sources: American Academy of Ophthalmology (AAO); Mayo Clinic; National Eye Institute (NEI)

Common Causes

Dry‑eye disease is usually multifactorial. Below are the most frequently identified contributors, grouped by underlying mechanism.

• Age‑related tear‑film decline: Tear production naturally decreases after age 50.
• Hormonal changes: Menopause, oral contraceptives, and hormone‑replacement therapy can alter tear composition.
• Autoimmune diseases: Sjögren’s syndrome, rheumatoid arthritis, systemic lupus erythematosus, and thyroid eye disease often cause severe dry eye.
• Meibomian gland dysfunction (MGD): Blocked or altered oil glands reduce the lipid layer, leading to rapid evaporation.
• Environmental factors: Low humidity, wind, air‑conditioning, and prolonged screen use increase tear evaporation.
• Contact lens wear: Long‑term lens use can disrupt the tear film and irritate the ocular surface.
• Medications: Antihistamines, decongestants, antidepressants, beta‑blockers, and isotretinoin decrease tear production.
• Ocular surgeries: LASIK, cataract extraction, or cataract‑related inflammation can transiently impair nerve feedback needed for tear secretion.
• Refractive errors & chronic blepharitis: Poor lid hygiene and eyelid inflammation affect tear distribution.
• Neurotrophic keratopathy: Damage to corneal nerves (e.g., from diabetes or trigeminal nerve injury) reduces reflex tearing.

Associated Symptoms

Patients with Kernouve disease often describe a constellation of uncomfortable sensations. Commonly reported symptoms include:

• Burning, stinging, or gritty feeling “as if something is in the eye.”
• Excessive tearing (reflex tearing) that paradoxically follows dryness.
• Blurred vision that improves after blinking.
• Redness of the conjunctiva (the white part of the eye).
• Sensitivity to light (photophobia).
• Difficulty wearing contact lenses.
• Eye fatigue, especially after reading or computer work.
• Stringy or mucus‑like discharge.

In severe cases, the surface of the cornea may develop tiny punctate lesions, ulcerations, or even scarring, leading to permanent visual loss.

When to See a Doctor

While occasional dryness is common, persistent or worsening symptoms warrant professional evaluation. Seek an eye‑care provider (optometrist or ophthalmologist) if you notice any of the following:

• Dryness lasting more than a few weeks despite over‑the‑counter lubricants.
• Frequent need to blink or close the eyes to clear vision.
• Redness that does not improve with artificial tears.
• Feeling of something gritty or a foreign body that does not resolve.
• Recurrent eye infections or corneal abrasions.
• Sudden worsening of vision or persistent blurred vision.
• History of autoimmune disease, recent eye surgery, or medication changes.

Early diagnosis can prevent complications such as corneal ulceration, scarring, or infection.

Diagnosis

Evaluating Kernouve disease involves a combination of patient history, symptom questionnaires, and objective tests performed in an eye‑clinic setting.

1. Clinical History & Symptom Scales

• Ocular Surface Disease Index (OSDI): A validated questionnaire that quantifies symptom severity and impact on daily life.
• Medication, systemic disease, and environmental exposure review.

2. Tear‑Film Evaluation

• Schirmer Test: Strips of filter paper placed under the lower eyelid for 5 minutes measure aqueous tear production. < 5 mm is considered abnormal.
• Phenol Red Thread Test: A thin thread changes color when wetted, offering a quicker assessment of tear volume.
• Tear Break‑Up Time (TBUT): Fluorescein dye is instilled; the time until the first dry spot appears is recorded. < 10 seconds suggests instability.
• Lipid Layer Interferometry: Specialized devices (e.g., LipiView) quantify the thickness of the lipid layer.

3. Ocular Surface Staining

• Fluorescein, lissamine green, or rose bengal dyes highlight epithelial damage, allowing clinicians to grade the severity using the Oxford or NEI scales.

4. Meibomian Gland Assessment

• Expression of glands, infrared meibography, or slit‑lamp evaluation to detect blockage or atrophy.

5. Laboratory Tests (when systemic disease is suspected)

• Autoantibody panels (ANA, SSA/SSB) for Sjögren’s syndrome.
• Rheumatoid factor, anti‑CCP, thyroid function tests.

Treatment Options

Treatment is individualized and often staged—from simple lubricants to advanced therapies—aimed at restoring a stable tear film, reducing inflammation, and protecting the ocular surface.

1. Environmental & Lifestyle Modifications

• Use a humidifier at home or work, especially in dry climates.
• Take regular “20‑20‑20” breaks during screen time (every 20 minutes look at something 20 feet away for 20 seconds).
• Avoid direct air flow from fans, heaters, or air‑conditioners toward the eyes.
• Wear wrap‑around sunglasses outdoors to reduce evaporation.
• Maintain lid hygiene: warm compresses followed by gentle lid scrubs with diluted baby shampoo.

2. Artificial Tears & Lubricants

• Preservative‑free drops are preferred for frequent use (up to 8–10 times/day).
• Gel or ointment formulations provide longer contact time, best used at night.
• Options include carboxymethylcellulose, hyaluronic acid, or polyvinyl alcohol based drops.

3. Anti‑Inflammatory Therapies

• Topical corticosteroids: Short courses (e.g., loteprednol) for acute inflammation.
• Cyclosporine A 0.05% (Restasis) or 0.1% (Cequa): Improves tear production by increasing ocular surface inflammation control.
• Lifitegrast (Xiidra): An integrin antagonist that reduces inflammatory cell trafficking.

4. Punctal Occlusion

• Insertion of temporary silicone plugs (or permanent cautery) into the puncta reduces tear drainage, increasing tear residence time.

5. Meibomian Gland Therapies

• Warm compresses (5–10 minutes) followed by gentle lid massage to melt and express blocked oil.
• In‑office procedures such as LipiFlow® thermal pulsation or intense pulsed light (IPL) therapy.

6. Autologous Serum Eye Drops

• For severe refractory cases, drops made from the patient’s own blood serum contain growth factors that promote epithelial healing.

7. Nutritional Supplements

• Omega‑3 fatty acids (e.g., fish oil 1000 mg BID) have modest evidence of improving tear quality.
• Lutein, zeaxanthin, and vitamin A can support ocular surface health.

8. Surgical Options (rare)

• Conjunctival grafts or epithelial transplantation for advanced keratopathy.

9. Home Care Strategies

• Stay hydrated—aim for 2 L of water daily.
• Limit caffeine and alcohol, which can dehydrate the body.
• Remove or adjust cosmetics that may irritate the eyelids.

Prevention Tips

While some risk factors (age, genetics) cannot be changed, many steps can reduce the likelihood of developing dry eye or mitigate its progression:

• Regular eye‑exam screening, especially if you have autoimmune disease or take systemic medications known to affect tears.
• Adopt the “blink‑more” habit during prolonged screen use; consider using software reminders.
• Maintain optimal eyelid hygiene—clean lids daily to prevent blepharitis.
• Protect eyes from environmental irritants: wear goggles when swimming, avoid smoke, and use protective eyewear in dusty settings.
• Choose preservative‑free artificial tears if you need frequent lubrication.
• Balance omega‑3 intake through diet (fatty fish, flaxseed) or supplements after discussing with your physician.
• If you are a contact‑lens wearer, follow replacement schedules and consider daily‑disposable lenses to reduce buildup.

Emergency Warning Signs

---

References:

• American Academy of Ophthalmology. Keratoconjunctivitis Sicca (Dry Eye) Diagnosis and Management. 2023.
• Mayo Clinic. “Dry eye.” Updated 2024.
• National Eye Institute (NEI). “Dry Eye Disease Fact Sheet.” 2022.
• Cleveland Clinic. “Dry Eye Syndrome.” Accessed June 2024.
• World Health Organization. “Vision Impairment and Blindness.” 2023.

```